LEXICON PHARMACEUTICALS INC
Latest Quote @ Wed May 5 10:25:33 (15 min delayed)
Last Day's Data
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of pharmaceutical products for the treatment of human disease. The company's drug candidates include LX6171, a Phase Ib clinical trial product for the treatment of cognitive impairment associated with disorders, such as Alzheimer's disease, schizophrenia, and vascular dementia; LX1031, a Phase Ia clinical trial product for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX2931, a preclinical development stage product for the treatment of autoimmune diseases, such as rheumatoid arthritis; and LX1032, a preclinical development stage product for the treatment of gastrointestinal disorders. It has also validated targets in drug discovery programs in various therapeutic areas, including diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize new small molecule drugs in the neuroscience field; Genentech, Inc. to discover novel therapeutic proteins and antibody targets; N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs; and Takeda Pharmaceutical Company Limited for the discovery of new drugs for the treatment of high blood pressure. Lexicon Pharmaceuticals, formerly known as Lexicon Genetics Incorporated, was founded in 1995 and changed its name to Lexicon Pharmaceuticals, Inc. in April 2007. The company is headquartered in The Woodlands, Texas.